Emphasis on accessible, low-toxicity treatments, including oral therapies, to reduce financial burden and improve patient ...
Epkinly combined with GemOx achieved durable remissions in relapsed/refractory DLBCL, addressing unmet needs in second-line ...
Orlowski serves as chairman, Ad Interim, and director of Myeloma in the Departments of Lymphoma/Myeloma and Experimental ...
Treatment with Zervyteg (MaaT013) generated encouraging results and demonstrated an acceptable safety profile in patients with acute graft-vs-host disease that affects the gastrointestinal tract and ...
Accurate information about Lynch syndrome is essential. As more people discuss hereditary cancer online, misinformation ...
Dr. Robert Orlowski says a single-drug option in newly diagnosed myeloma may offer strong responses with fewer side effects and preserve future treatments.
A clinical trial found that Jaypirca was more effective than Imbruvica across the frontline and relapsed/refractory CLL/SLL settings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback